Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Melanoma × pembrolizumab × Dermatologic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 268 Carcinoma, Non-Small-Cell Lung 67 Squamous Cell Carcinoma of Head and Neck 52 Carcinoma, Renal Cell 52 Neoplasms 35 Colorectal Neoplasms 35 Neoplasm Metastasis 30 Stomach Neoplasms 27 Carcinoma, Merkel Cell 26 Triple Negative Breast Neoplasms 25 Ovarian Neoplasms 24 Skin Neoplasms 23 Carcinoma, Transitional Cell 22 Uterine Cervical Neoplasms 21 Head and Neck Neoplasms 21 Lung Neoplasms 19 Carcinoma, Hepatocellular 18 Breast Neoplasms 18 Esophageal Neoplasms 17 Parkinson Disease 4, Autosomal Dominant Lewy Body 16 Pancreatic Neoplasms 14 Urinary Bladder Neoplasms 12 Uveal Melanoma 11 Small Cell Lung Carcinoma 11 Sarcoma 11 Lymphoma 11 Brain Neoplasms 11 Kidney Neoplasms 10 Endometrial Neoplasms 10 Prostatic Neoplasms 8

Interventions

pembrolizumab 1 Temozolomide 1 Paclitaxel 1 Dacarbazine 1 Cisplatin 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03407170 2020-07-15

KEYNOTE-161

Merck Sharp & Dohme LLC

Phase 2 Terminated

1 enrolled 3 charts

Advanced Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡